List of Figures
Figure 1: Breast Cancer, Global, Innovation Trends in Product Approvals Across the Pharmaceutical Market, 1987–2014 7
Figure 2: Breast Cancer, Global, Post-Marketing-Approval Sales Performance of First-in-Class Products Across the Pharmaceutical Industry ($m), 2006–2013 8
Figure 3: Breast Cancer, Global, Treatment Algorithm for Cancer Diagnosed at Stages I to III, 2018 21
Figure 4: Breast Cancer, Global, Treatment Algorithm for Cancer Diagnosed at Stage IV, 2018 22
Figure 5: Breast Cancer, Global, Market by Molecule Type and Molecular Target, 2018 27
Figure 6: Breast Cancer, Global, Pipeline Size by Therapy Area, 2018 29
Figure 7: Breast Cancer, Global, Pipeline by Stage of Development and Molecule Type, 2018 30
Figure 8: Breast Cancer, Global, Pipeline by Molecular Target and Breakdown of Growth Factor Antagonist Molecular Target Class, 2018 31
Figure 9: Breast cancer, Global, Distribution of Pipeline and Marketed Products by Molecular Target Class, 2018 32
Figure 10: Breast Cancer, Global, Distribution of Pipeline Products by First-in-Class Status and Molecular Target Class, 2018 34
Figure 11: Breast Cancer, Global, Percentage Distribution of First-in-Class and Non-First-in-Class Products by Stage of Development and Molecular Target Class, 2018 36
Figure 12: Breast Cancer, Global, Ratio of First-in-Class Products to First-in-Class Targets by Stage of Development and Molecular Target Class, 2018 37
Figure 13: Breast Cancer, Global, All First-in-Class Pipeline Programs, 2018 (part 1) 38
Figure 14: Breast Cancer, Global, All First-in-Class Pipeline Programs, 2018 (part 2) 39
Figure 15: Breast Cancer, Global, All First-in-Class Pipeline Programs, 2018 (part 3) 40
Figure 16: Breast Cancer, Global, All First-in-Class Pipeline Programs, 2018 (part 4) 41
Figure 17: Breast Cancer, Global, All First-in-Class Pipeline Programs, 2018 (part 5) 42
Figure 18: Breast Cancer, Global, All First-in-Class Pipeline Programs, 2018 (part 6) 43
Figure 19: Breast Cancer, Global, All First-in-Class Pipeline Programs, 2018 (part 7) 44
Figure 20: Breast Cancer, Global, All First-in-Class Pipeline Programs, 2018 (part 8) 45
Figure 21: Breast Cancer, Global, All First-in-Class Pipeline Programs, 2018 (part 9) 46
Figure 22: Breast Cancer, Global, All First-in-Class Pipeline Programs, 2018 (part 10) 47
Figure 23: Breast Cancer, Global, All First-in-Class Pipeline Programs, 2018 (part 11) 48
Figure 24: Breast Cancer, Global, All First-in-Class Pipeline Programs, 2018 (part 12) 49
Figure 25: Breast Cancer, Global, All First-in-Class Pipeline Programs, 2018 (part 13) 50
Figure 26: Breast Cancer, Global, All First-in-Class Pipeline Programs, 2018 (part 14) 51
Figure 27: Breast Cancer, Global, All First-in-Class Pipeline Programs, 2018 (part 15) 52
Figure 28: Breast Cancer, Global, All First-in-Class Pipeline Programs, 2018 (part 16) 53
Figure 29: Breast Cancer, Global, All First-in-Class Pipeline Programs, 2018 (part 17) 54
Figure 30: Breast Cancer, Global, All First-in-Class Pipeline Programs, 2018 (part 18) 55
Figure 31: Breast Cancer, Global, All First-in-Class Pipeline Programs, 2018 (part 19) 56
Figure 32: Breast Cancer, Global, All First-in-Class Pipeline Programs, 2018 (part 20) 57
Figure 33: Breast Cancer, Global, All First-in-Class Pipeline Programs, 2018 (part 21) 58
Figure 34: Breast Cancer, Global, All First-in-Class Pipeline Programs, 2018 (part 22) 59
Figure 35: Breast Cancer, Global, All First-in-Class Pipeline Programs, 2018 (part 23) 60
Figure 36: Breast Cancer, Global, All First-in-Class Pipeline Programs, 2018 (part 24) 61
Figure 37: Breast Cancer, Global, First-in-Class Molecular Target Matrix Assessment for Breast Cancer, 2018 (part 1) 64
Figure 38: Breast Cancer, Global, First-in-Class Molecular Target Matrix Assessment for Breast Cancer, 2018 (part 2) 65
Figure 39: Breast Cancer, Global, First-in-Class Molecular Target Matrix Assessment for Breast Cancer, 2018 (part 3) 66
Figure 40: Breast Cancer, Global, First-in-Class Molecular Target Matrix Assessment for Breast Cancer, 2018 (part 4) 67
Figure 41: Breast Cancer, Global, First-in-Class Molecular Target Matrix Assessment for Breast Cancer, 2018 (part 5) 68
Figure 42: Breast Cancer, Global, First-in-Class Molecular Target Matrix Assessment for Breast Cancer, 2018 (part 6) 68
Figure 43: Breast Cancer, Global, First-in-Class Molecular Target Matrix Assessment for Breast Cancer, 2018 (part 7) 69
Figure 44: Breast Cancer, Global, Industry-Wide Licensing Deals by First-in-Class Status and Stage of Development, 2006–2015 83
Figure 45: Breast Cancer, Global, Industry-Wide Licensing Deals by First-in-Class Status, Deal Value, Upfront Payment Value and Stage of Development, 2006–2014 84
Figure 46: Breast Cancer, Global, Licensing Deals by Region, Value and Year, 2006–2018 86
Figure 47: Breast Cancer, Global, Licensing Deals by Deal Value, Upfront Payment Value and Stage of Development, 2006–2018 87
Figure 48: Breast Cancer, Global, Number and Aggregate Deal Value of Licensing Deals by Molecule Type and Molecular Target Class, 2006–2018 88
Figure 49: Breast Cancer, Global, Licensing Deals with Disclosed Deal Values, 2006–2018 (part 1) 89
Figure 50: Breast Cancer, Global, Licensing Deals with Disclosed Deal Values, 2006–2018 (part 2) 90
Figure 51: Breast Cancer, Global, Licensing Deals with Disclosed Deal Values, 2006–2018 (part 3) 91
Figure 52: Breast Cancer, Global, Co-development Deals by Region, Value and Year, 2006–2018 92
Figure 53: Breast Cancer, Global, Number and Aggregate Deal Value of Co-development Deals by Stage of Development and Year, 2006–2018 93
Figure 54: Breast Cancer, Global, Number and Aggregate Deal Value of Co-development Deals by Molecule Type and Molecular Target Class, 2006–2018 94
Figure 55: Breast Cancer, Global, Number and Aggregate Deal Value of Co-development Deals by Molecule Type and Molecular Target Class, 2006–2018 95
Figure 56: Breast Cancer, Global, First-in-Class Programs with and without Prior Involvement in Licensing or Co-development Deals, 2006–2018 (part 1) 96
Figure 57: Breast Cancer, Global, First-in-Class Programs with and without Prior Involvement in Licensing or Co-development Deals, 2006–2018 (part 2) 97
Figure 58: Breast Cancer, Global, First-in-Class Programs with and without Prior Involvement in Licensing or Co-development Deals, 2006–2018 (part 3) 98
Figure 59: Breast Cancer, Global, First-in-Class Programs with and without Prior Involvement in Licensing or Co-development Deals, 2006–2018 (part 4) 99
Figure 60: Breast Cancer, Global, First-in-Class Programs with and without Prior Involvement in Licensing or Co-development Deals, 2006–2018 (part 5) 100
Figure 61: Breast Cancer, Global, First-in-Class Programs with and without Prior Involvement in Licensing or Co-development Deals, 2006–2018 (part 6) 101
Figure 62: Breast Cancer, Global, First-in-Class Programs with and without Prior Involvement in Licensing or Co-development Deals, 2006–2018 (part 7) 102
Figure 63: Breast Cancer, Global, First-in-Class Programs with and without Prior Involvement in Licensing or Co-development Deals, 2006–2018 (part 8) 103
Figure 64: Breast Cancer, Global, First-in-Class Programs with and without Prior Involvement in Licensing or Co-development Deals, 2006–2018 (part 9) 104
Figure 65: Breast Cancer, Global, First-in-Class Programs with and without Prior Involvement in Licensing or Co-development Deals, 2006–2018 (part 10) 104